Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 11/20 | 0.56 |
| ▸ | NFE2L2 | Q16236 | 10/20 | 0.56 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.47 |
| ▸ | AVPR1B | P47901 | 1/20 | 0.47 |
| ▸ | BACE1 | P56817 | 1/20 | 0.47 |
| ▸ | MMP13 | P45452 | 3/20 | 0.46 |
| ▸ | MMP2 | P08253 | 1/20 | 0.46 |
| ▸ | MMP3 | P08254 | 1/20 | 0.46 |
| ▸ | MMP1 | P03956 | 2/20 | 0.46 |
| ▸ | MMP9 | P14780 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7355017 | 0.90 | KEAP1 (0.48) | KEAP1NFE2L2KCNA5ALDH1A1TSHR | |
| SCHEMBL7342866 | 0.88 | CNR1 (0.60) | KEAP1NFE2L2KCNA5ALDH1A1TSHR | |
| SCHEMBL7351711 | 0.85 | KCNA5 (0.53) | KEAP1NFE2L2KCNA5ALDH1A1TSHR | |
| SCHEMBL1583272 | 0.80 | MAPT (0.47) | KEAP1NFE2L2ALDH1A1TSHRMMP13 | |
| SCHEMBL7349521 | 0.77 | CNR1 (0.47) | KEAP1NFE2L2KCNA5ALDH1A1TSHR | |
| SCHEMBL6413655 | 0.77 | MMP3 (0.66) | ALDH1A1TSHRHTTATMCNR1 | |
| SCHEMBL7346430 | 0.76 | KEAP1 (0.44) | KEAP1NFE2L2KCNA5ALDH1A1TSHR | |
| SCHEMBL3503903 | 0.76 | KEAP1 (0.76) | KEAP1NFE2L2MEP1BMMP13MMP2 | |
| SCHEMBL8042848 | 0.76 | KEAP1 (0.55) | KEAP1NFE2L2KCNA5MEP1BAVPR1B | |
| SCHEMBL937908 | 0.75 | MEN1 (0.48) | KEAP1NFE2L2TSHRHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0873312-B1 | ALPHA-SUBSTITUTED ARYLSULPHONAMIDO HYDROXAMIC ACIDS AS TNF-ALPHA AND MATRIX METALLOPROTEINASE INHIBITORS | NOVARTIS AG (CH) | 2002-06-12 | — | — | EP | disclosed |
| EP-0766672-B1 | ARYLSULFONAMIDO-SUBSTITUTED HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS | NOVARTIS AG (CH) | 2000-10-04 | — | — | EP | disclosed |
| EP-0873312-A1 | ALPHA-SUBSTITUTED ARYLSULPHONAMIDO HYDROXAMIC ACIDS AS TNF-ALPHA AND MATRIX METALLOPROTEINASE INHIBITORS | Novartis AG (CH) | 1998-10-28 | — | — | EP | disclosed |
| US-5770624-A | INHIBITORS OF TUMOR NECROSIS FACTOR ALPHA AND MATRIX DEGRADING METALLOPROTEINEASE ACTIVITY | NOVARTIS CORP. (US) | 1998-06-23 | — | — | US | disclosed |
| US-5672615-A | MATRIX-DEGRADING METALLOPROTEINASE INHIBITORS | NOVARTIS CORPORATION (US) | 1997-09-30 | — | — | US | disclosed |
| US-5646167-A | ADMINISTERED AS METALLOPROTEINASE INHIBITOR, ANTITUMOR OR ANTICARCINOGENIC AGENT | CIBA-GEIGY CORPORATION (US) | 1997-07-08 | — | — | US | disclosed |
| WO-1997022587-A1 | ALPHA-SUBSTITUTED ARYLSULPHONAMIDO HYDROXAMIC ACIDS AS TNF-ALPHA AND MATRIX METALLOPROTEINASE INHIBITORS | NOVARTIS AG (CH) | 1997-06-26 | — | — | WO | disclosed |
| EP-0766672-A1 | ARYLSULFONAMIDO-SUBSTITUTED HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS | Novartis AG (CH) | 1997-04-09 | — | — | EP | disclosed |
| US-5552419-A | METALLOPROTEINASE INHIBITORS | CIBA-GEIGY CORPORATION (US) | 1996-09-03 | — | — | US | disclosed |
| US-5506242-A | METALLOELASTASE INHIBITOR; TREATS EMPHYSEMA | CIBA-GEIGY CORPORATION (US) | 1996-04-09 | — | — | US | disclosed |
| WO-1996000214-A1 | ARYLSULFONAMIDO-SUBSTITUTED HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS | CIBA-GEIGY AG (CH) | 1996-01-04 | — | — | WO | disclosed |